CymaBay Therapeutics, Inc.
0I5P.L
London Stock Exchange32.48
USD
+0.00
- -
CymaBay Therapeutics, Inc.
0I5P.L
(London Stock Exchange)
Recent
price
32.48
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- CymaBay Therapeutics, Inc. (Ticker: 0I5P.L) is a clinical-stage biopharmaceutical company that develops therapies for patients with liver and other chronic diseases exhibiting high unmet medical needs; its lead product candidate is seladelpar (MBX-8025), a potent, selective, orally active peroxisome proliferator-activated receptor delta (PPARδ) agonist in phase III development for primary biliary cholangitis (PBC), including pruritus; additional pipeline candidates include MBX-2982 for hypoglycemia in type 1 diabetes and earlier-stage programs such as CB-0406 and CB-001 targeting liver and metabolic disorders. CymaBay Therapeutics focuses on the biotechnology sector, serving patients with autoimmune liver diseases like PBC, nonalcoholic steatohepatitis (NASH), and related chronic conditions through investigational therapies that address bile acid synthesis, lipid metabolism, inflammation, and fibrosis. The company, founded in 1988 and formerly known as Metabolex, Inc., operated independently with headquarters in Newark, California, until Gilead Sciences, Inc. completed its acquisition in March 2024 for approximately $4.3 billion, after which CymaBay functions as a wholly owned subsidiary of Gilead with seladelpar integrated into Gilead's liver disease portfolio.